Announces completion of enrollment in its oral allergen challenge study for the development of its late-stage pipeline program, Anaphylm™ (epinephrine) Sublingual FilmOutlines the development strategy for the Company’s next pipeline product candidate, AQST-108 (epinephrine) Topical Gel for the treatment of Alopecia areataHolds virtual investor day WARREN, N.J., Sept. 27, 2024 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ: AQST) (“Aquestive” or the “Company”), a pharmaceutical company advancing me ...

WARREN, N.J., Sept. 09, 2024 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ: AQST) (“Aquestive” or the “Company”), a pharmaceutical company advancing medicines to bring meaningful improvement to patients' lives through innovative science and delivery technologies, today announced it will hold a virtual investor day on September 27, 2024 at 8:00 am ET to discuss the Company’s pipeline updates, inclusive of Anaphylm™ (epinephrine) Sublingual Film and AQST-108 (epinephrine) Topical Gel, both candidat ...

teekid It has been over four months since my last Aquestive Therapeutics (NASDAQ:AQST) article, where I went over Anaphylm's Phase III data and the possibility for the company to send in an NDA to the FDA this year. Furthermore, I pointed out that Anaphylm's trip through the FDA's regulatory path unearthed several potent catalysts that could offer some attractive trading opportunities for AQST investors. Following that article, I watched AQST experience selling pressure, but the ticker is now trading above ...

WARREN, N.J., Aug. 22, 2024 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ: AQST) (“Aquestive” or the “Company”), a pharmaceutical company advancing medicines to bring meaningful improvement to patients' lives through innovative science and delivery technologies, announced today that the management team will participate in two upcoming investor conferences in September 2024 as follows: H.C. Wainwright 26th Annual Global Investor Conference: presentation at 8:30 am ET on Monday, September 9th and a ...

AndreyPopov Shares of pharmaceutical company, Aquestive Therapeutics (NASDAQ:AQST) jumped 137.29% (YoY) after the Food and Drug Administration (FDA) approved rival company ARS Pharmaceuticals' (SPRY) "epinephrine nasal spray" also called Neffy. This drug is the first nasal spray to be authorized for emergency allergic reactions (anaphylaxis) giving a substitute to auto-injectors known as EpiPens. In this article, I will explain why this is the right time to buy AQST stock due to the company's robust res ...

Aquestive Therapeutics Inc. (NASDAQ:AQST) Q2 2024 Earnings Conference Call August 7, 2024 8:00 AM ET Company Participants Bennett Watson - ICR Westwicke Investor Relations Dan Barber - Chief Executive Officer Ernie Toth - Chief Financial Officer Carl Kraus - Chief Medical Officer Stephen Wargacki - Chief Science Officer Sherry Korczynski - Senior Vice President of Sales and Marketing Conference Call Participants Roanna Ruiz - Leerink Partners David Amsellem - Piper Sandler François Brisebois - Oppenheimer R ...

For the quarter ended June 2024, Aquestive Therapeutics (AQST) reported revenue of $20.1 million, up 51.8% over the same period last year. EPS came in at -$0.03, compared to -$0.10 in the year-ago quarter.The reported revenue compares to the Zacks Consensus Estimate of $12.62 million, representing a surprise of +59.31%. The company delivered an EPS surprise of +72.73%, with the consensus EPS estimate being -$0.11.While investors scrutinize revenue and earnings changes year-over-year and how they compare wit ...

Aquestive Therapeutics (AQST) came out with a quarterly loss of $0.03 per share versus the Zacks Consensus Estimate of a loss of $0.11. This compares to loss of $0.10 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of 72.73%. A quarter ago, it was expected that this specialty pharmaceutical company would post a loss of $0.09 per share when it actually produced a loss of $0.17, delivering a surprise of -88.89%.Over the last four q ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Title of each class Trading Symbol(s) Name of each exchange on which registered Common Stock, par value $0.001 per share AQST NASDAQ Global Market FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _____ to _____ Commissi ...

Exhibit 99.1 Aquestive Therapeutics Reports Second Quarter 2024 Financial Results and Provides Business Update • Late-stage pipeline program, Anaphylm™ (epinephrine) Sublingual Film, remains on track for a near-term New Drug Application (NDA) submission to the FDA • Expanded sales coverage for Libervant™ (diazepam) Buccal Film for patients between ages two to five with national retail distribution anticipated in the fourth quarter 2024 • Anticipates holding epinephrine prodrug technology investor day in the ...